111
Views
13
CrossRef citations to date
0
Altmetric
Original Research

Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH

, , , , , , , & show all
Pages 141-150 | Published online: 20 Dec 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Yoshio Sumida, Masato Yoneda, Yuji Ogawa, Masashi Yoneda, Takeshi Okanoue & Atsushi Nakajima. (2020) Current and new pharmacotherapy options for non-alcoholic steatohepatitis. Expert Opinion on Pharmacotherapy 21:8, pages 953-967.
Read now
Danny Issa, Julia Wattacheril & Arun J. Sanyal. (2017) Treatment options for nonalcoholic steatohepatitis - a safety evaluation. Expert Opinion on Drug Safety 16:8, pages 903-913.
Read now
Salvatore Sutti, Stefania Bruzzì & Emanuele Albano. (2016) The role of immune mechanisms in alcoholic and nonalcoholic steatohepatitis: a 2015 update. Expert Review of Gastroenterology & Hepatology 10:2, pages 243-253.
Read now

Articles from other publishers (10)

Man Wang, Lei Li, Yannan Xu, Juan Du & Changquan Ling. (2022) Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis. Frontiers in Pharmacology 13.
Crossref
Puru Rattan & Vijay H. Shah. (2022) Review article: current and emerging therapies for acute alcohol‐associated hepatitis. Alimentary Pharmacology & Therapeutics 56:1, pages 28-40.
Crossref
Naomi F. Lange & Jean-François Dufour. 2022. Nicht-alkoholische Fettlebererkrankung. Nicht-alkoholische Fettlebererkrankung 227 255 .
Jingguo Li & Biguang Tuo. (2021) Current and Emerging Approaches for Hepatic Fibrosis Treatment. Gastroenterology Research and Practice 2021, pages 1-13.
Crossref
Siddhi Bagwe-Parab, Pratik Yadav, Ginpreet Kaur, Hardeep Singh Tuli & Harpal Singh Buttar. (2020) Therapeutic Applications of Human and Bovine Colostrum in the Treatment of Gastrointestinal Diseases and Distinctive Cancer Types: The Current Evidence. Frontiers in Pharmacology 11.
Crossref
Nahum Mendez-Sanchez, Vania Cruz-Ramon, Oscar Ramirez-Perez, Jessica Hwang, Beatriz Barranco-Fragoso & Jaqueline Cordova-Gallardo. (2018) New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis. International Journal of Molecular Sciences 19:7, pages 2034.
Crossref
Somaya Albhaisi & Arun Sanyal. (2018) Recent advances in understanding and managing non-alcoholic fatty liver disease. F1000Research 7, pages 720.
Crossref
Marco Poeta, Luca Pierri & Pietro Vajro. (2017) Gut–Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. Children 4:8, pages 66.
Crossref
Luisa Vonghia. (2015) Cross talk of the immune system in the adipose tissue and the liver in non-alcoholic steatohepatitis: Pathology and beyond. World Journal of Hepatology 7:15, pages 1905.
Crossref
Won Kim. (2014) Severe alcoholic hepatitis-current concepts, diagnosis and treatment options. World Journal of Hepatology 6:10, pages 688.
Crossref